GLS and breast cancer: Drug metabolism associated studies have shown that CB-839 inhibits the activity of GLS, thereby restricting glutamine derivatives from entering the TCA cycle (105), so it has a significant inhibitory effect on the growth of breast cancer, soft tissue sarcoma and other malignant cells (106, 107).